Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Reigner

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
British Journal of Clinical Pharmacology|September 11, 2018
Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian childrenTrevor N Johnson, Yumi Cleary, Neil Parrott, et al.
Pharmaceutical Statistics|July 11, 2017
Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacyWai Yin Yeung, Bruno Reigner, Ulrich Beyer, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 10, 2019
Generics in transplantation medicine: Randomized comparison of innovator and substitution products containing mycophenolate mofetil
Bruno Reigner, Susan Grange, Darren Bentley, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney diseaseIain C Macdougall, Richard Robson, Sylvie Opatrna, et al.
Cancer Chemotherapy and Pharmacology|April 6, 2002
Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patientsChristopher Poole, Jill Gardiner, Chris Twelves, et al.
British Journal of Clinical Pharmacology|February 18, 2014
Bayesian adaptive designs in single ascending dose trials in healthy volunteersDavid Guédé, Bruno Reigner, Francois Vandenhende, et al.
British Journal of Clinical Pharmacology|November 27, 2019
Model-based approach for methoxy polyethylene glycol-epoetin beta drug development in paediatric patients with anaemia of chronic kidney diseasePascal Chanu, Franz Schaefer, Bradley A Warady, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2003
Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancerBruno Reigner, Toru Watanabe, Johannes Schüller, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
British Journal of Clinical Pharmacology|September 11, 2018
Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian childrenTrevor N Johnson, Yumi Cleary, Neil Parrott, et al.
Pharmaceutical Statistics|July 11, 2017
Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacyWai Yin Yeung, Bruno Reigner, Ulrich Beyer, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 10, 2019
Generics in transplantation medicine: Randomized comparison of innovator and substitution products containing mycophenolate mofetil
Bruno Reigner, Susan Grange, Darren Bentley, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney diseaseIain C Macdougall, Richard Robson, Sylvie Opatrna, et al.
Cancer Chemotherapy and Pharmacology|April 6, 2002
Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patientsChristopher Poole, Jill Gardiner, Chris Twelves, et al.
British Journal of Clinical Pharmacology|February 18, 2014
Bayesian adaptive designs in single ascending dose trials in healthy volunteersDavid Guédé, Bruno Reigner, Francois Vandenhende, et al.
British Journal of Clinical Pharmacology|November 27, 2019
Model-based approach for methoxy polyethylene glycol-epoetin beta drug development in paediatric patients with anaemia of chronic kidney diseasePascal Chanu, Franz Schaefer, Bradley A Warady, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2003
Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancerBruno Reigner, Toru Watanabe, Johannes Schüller, et al.
Pageof 2